Ganymed

Ganymed Pharmaceuticals is a biopharmaceutical company developing therapeutic agents designed to kill tumor cells without harming healthy tissue. Its mission is to revolutionize cancer treatment by developing a new class of therapeutics called Ideal Monoclonal Antibodies (IMABs). The uniqueness of IMABs lies in their high selectivity for proteins present on tumor cells but not binding to healthy cells. This unparalleled tumor cell specificity makes IMABs selective for cancer cells, enabling them to effectively kill tumor cells without damaging normal healthy tissue. As a result, they can be administered at optimal doses, offering a broad therapeutic window and reducing the risk of side effects.